サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1139889

移植片対宿主病市場：製品タイプ別、治療タイプ別、エンドユーザー別：世界の機会分析および産業予測、2021-2031年

Graft Versus Host Disease Market By Product Type, By Treatment Type, By End Use : Global Opportunity Analysis and Industry Forecast, 2021-2031
出版日: | 発行: Allied Market Research | ページ情報: 英文 230 Pages | 納期: 2～3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=158.97円
移植片対宿主病市場：製品タイプ別、治療タイプ別、エンドユーザー別：世界の機会分析および産業予測、2021-2031年
出版日: 2022年06月01日
発行: Allied Market Research
ページ情報: 英文 230 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の移植片対宿主病市場は、2021年に29億6860万米ドルと評価され、2031年には103億7530万米ドルに達し、2022年から2031年までCAGR13.5%で成長すると予測されています。

移植片対宿主病（GVHD）とは、同種移植（骨髄移植）後に発症する可能性のある病態です。GVHDでは、提供された骨髄や末梢血幹細胞がレシピエントの体を異物とみなし、提供された細胞・骨髄が体を攻撃します。GVHDには、急性移植片対宿主病（aGVHD）と慢性移植片対宿主病（cGVHD）の2つの病型があります。

aGVHDとcGVHDの病態生理は、まだ不完全に理解されています。すなわち、腸粘膜や肝臓などの宿主組織を損傷する条件付け療法、宿主抗原に対するドナーT細胞の活性化とそれに続くクローン性T細胞の拡大、インターロイキン1（IL-1）や腫瘍壊死因子（TNFα）などの炎症性サイトカインの放出が、さらなる宿主組織損傷を引き起こすというものです。cGVHDの発症には、ドナー由来の同種反応性T細胞、自己反応性T細胞、宿主に対する抗体を産生するB細胞の残存や、末端臓器の線維化を引き起こす慢性炎症のメカニズムなど、いくつかのメカニズムが関与しています。

数十年にわたる研究と移植後の免疫抑制療法の改善にもかかわらず、移植片対宿主病（GVHD）は依然として同種造血幹細胞移植（HSCT）レシピエントの病的状態および死亡率の重大な原因となっています。

COVID-19の大流行は、世界中のさまざまなビジネスに影響を及ぼしています。移植片対宿主病市場も大きな影響を及ぼしました。COVID-19の蔓延を食い止めるため、世界各国の政府は国境の封鎖、監禁、厳しい社会的距離の取り方など、厳しい規制を実施しました。これらの措置は世界経済に大きな影響を与え、さまざまな産業に影響を及ぼしました。製薬会社やバイオテクノロジー企業は、世界中の政府とともに、ワクチン開発の支援から医薬品のサプライチェーンの課題に対する計画まで、COVID-19の発生に対処するために取り組んでいます。現在、約115のワクチン候補と155の分子が研究開発パイプラインにあります。

COVID-19のインパクトCOVID-19のパンデミックは、米国および世界の腎臓移植の状況を大きく変えました。今回のパンデミックは、腎移植後のレシピエントの同種移植片および患者さんの生存に悪影響を与えただけでなく、移植の紹介やリストアップ、臓器提供率、臓器の調達と出荷、待機者死亡率など、移植医療のあらゆる側面に影響を及ぼしています。

腎臓移植率が低下するにつれて、臓器調達率も低下しました。英国では、OPOへの臓器紹介が39％減少したと報告されています。フランスは、すべての死者臓器調達率が以前と比較して16％減少したと報告しました。これらの減少の一部は、検査能力の不足とCOVID-19検査結果の遅れ、手術室の利用可能性の制限、人員と保護具を守るために必要ない臨床活動の回避を義務付けるなど、移植プログラムや組織が直面する調達上の課題によるものです。

したがって、COVID-19の全体的な影響は、移植手術の件数の減少により、移植片対宿主病市場には依然としてマイナスです。移植手術では、患者との密接な接触を伴う再使用可能な器具を日常的に使用する必要があります。このため、疾病伝播のリスクが高まる。

移植片対宿主病の増加は、主に同種移植の増加に起因しています。また、疾患診断率の上昇や移植片対宿主病の治療に使用できる製品の増加も、市場の成長を後押しする要因となっています。

臓器調達・移植ネットワークの速報データによると、2020年、米国における死亡ドナーからの臓器提供は過去最高を記録しました。合計12,587人が、他人の命を救い、高めるために1つ以上の臓器を提供し、2019年より6%増加しました。

さらに、故人提供の増加の多くは、従来の医療基準よりも低い基準を示すドナーによって実現されました。故人ドナーの最も多い年齢層は、50～64歳でした。このカテゴリーのドナー3,726人は、2019年に比べて7.9%増加しました。脳死とは対照的に心肺機能不全で死亡した人の間で提供が大幅に増加し、心肺機能不全死後のドナー（DCDドナー）3,223人は、2019年の合計より18.6％増加しました。

臓器提供統計によると、全国の移植待機者数は10万5988人で、一方、臓器移植を待っている人は毎日17人死亡し、2021年には推定4万件の移植が実施されました。

計算生物学では検出できないアレルギー反応などの術後合併症、政府の不利なシナリオ、機器の高い初期費用と維持費、標準化の欠如、熟練労働者の不足などが、予測期間中の市場成長の大きな阻害要因になると予想されます。

移植片対宿主病市場は、製品、診断、タイプ、最終用途、地域に基づいて区分されます。製品別では、コルチコステロイド、モノクローナル抗体、免疫抑制剤、その他に区分されます。タイプ別では、急性期と慢性期に区分されます。エンドユーズでは、病院薬局、小売薬局、オンライン薬局に区分されます。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場の概要

  • 市場の定義と範囲
  • 主な調査結果
    • 主な投資ポケット
  • ポーターのファイブフォース分析
  • 主要企業のポジショニング
  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会
  • COVID-19 影響分析

第4章 移植片対宿主病市場：製品タイプ別

  • 概要
    • 市場規模および予測
  • コルチコステロイド
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場分析：国別
  • モノクローナル抗体
    • 主要な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場分析：国別
  • 免疫抑制剤
    • 主要な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場分析：国別
  • その他
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場分析：国別

第5章 移植片対宿主病市場：治療法タイプ別

  • 概要
    • 市場規模および予測
  • 急性GVHD
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場分析：国別
  • 慢性GVHD
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場分析：国別

第6章 移植片対宿主病市場：エンドユーザー別

  • 概要
    • 市場規模・予測
  • 病院薬局
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場分析：国別
  • 小売薬局
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場分析：国別
  • オンライン薬局
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場分析：国別

第7章 移植片対宿主病市場：地域別

  • 概要
    • 市場規模・予測
  • 北米
    • 主な動向と機会
    • 北米市場規模・予測：製品タイプ別
    • 北米市場規模・予測：治療タイプ別
    • 北米市場規模・予測：エンドユース別
    • 北米市場規模・予測：国別
      • 米国
      • カナダ
      • メキシコ
  • 欧州
    • 主な動向と機会
    • 欧州市場規模・予測：製品タイプ別
    • 欧州市場規模・予測：治療タイプ別
    • 欧州市場規模・予測：エンドユース別
    • 欧州市場規模・予測：国別
      • ドイツ
      • フランス
      • 英国
      • イタリア
      • スペイン
      • その他の欧州地域
  • アジア太平洋地域
    • 主な動向と機会
    • アジア太平洋地域の市場規模・予測：製品タイプ別
    • アジア太平洋地域の市場規模・予測：治療タイプ別
    • アジア太平洋地域の市場規模・予測：エンドユース別
    • アジア太平洋地域の市場規模・予測：国別
      • 日本
      • 中国
      • オーストラリア
      • インド
      • 韓国
      • その他アジア太平洋地域
  • LAMEA
    • 主な動向と機会
    • LAMEAの市場規模・予測：製品タイプ別
    • LAMEAの市場規模・予測：治療タイプ別
    • LAMEAの市場規模・予測：エンドユース別
    • LAMEAの市場規模・予測：国別
      • ブラジル
      • トルコ
      • 南アフリカ
      • LAMEAの残りの地域

第8章 企業情勢

  • イントロダクション
  • 主要成功戦略
  • 主要10社の製品マッピング
  • 競合ダッシュボード
  • 競合のヒートマップ
  • 主な発展

第9章 企業プロファイル

  • Sanofi
  • Novartis AG
  • Merck & Co.
  • Abbvie Inc
  • Pfizer Inc.
  • Accord Healthcare Limited
  • Bristol Myer Squibb
  • Asahi Kasei Corporation
  • Glaxosmithkline plc
  • Incyte Corporation
図表

LIST OF TABLES

  • TABLE 1. GLOBAL GRAFT VERSUS HOST DISEASE MARKET, BY PRODUCT TYPE, 2021-2031,($MILLION)
  • TABLE 2. GRAFT VERSUS HOST DISEASE MARKET REVENUE, FOR CORTICOSTEROIDS, BY REGION , 2021-2031,($MILLION)
  • TABLE 3. GRAFT VERSUS HOST DISEASE MARKET FOR CORTICOSTEROIDS BY COUNTRY, 2021-2031,($MILLION)
  • TABLE 4. GRAFT VERSUS HOST DISEASE MARKET REVENUE, FOR MONOCLONAL ANTIBODIES, BY REGION , 2021-2031,($MILLION)
  • TABLE 5. GRAFT VERSUS HOST DISEASE MARKET FOR MONOCLONAL ANTIBODIES BY COUNTRY, 2021-2031,($MILLION)
  • TABLE 6. GRAFT VERSUS HOST DISEASE MARKET REVENUE, FOR IMMUNOSUPPRESSANTS, BY REGION , 2021-2031,($MILLION)
  • TABLE 7. GRAFT VERSUS HOST DISEASE MARKET FOR IMMUNOSUPPRESSANTS BY COUNTRY, 2021-2031,($MILLION)
  • TABLE 8. GRAFT VERSUS HOST DISEASE MARKET REVENUE, FOR OTHERS, BY REGION , 2021-2031,($MILLION)
  • TABLE 9. GRAFT VERSUS HOST DISEASE MARKET FOR OTHERS BY COUNTRY, 2021-2031,($MILLION)
  • TABLE 10. GLOBAL GRAFT VERSUS HOST DISEASE MARKET, BY TREATMENT TYPE, 2021-2031,($MILLION)
  • TABLE 11. GRAFT VERSUS HOST DISEASE MARKET REVENUE, FOR ACUTE GVHD, BY REGION , 2021-2031,($MILLION)
  • TABLE 12. GRAFT VERSUS HOST DISEASE MARKET FOR ACUTE GVHD BY COUNTRY, 2021-2031,($MILLION)
  • TABLE 13. GRAFT VERSUS HOST DISEASE MARKET REVENUE, FOR CHRONIC GVHD, BY REGION , 2021-2031,($MILLION)
  • TABLE 14. GRAFT VERSUS HOST DISEASE MARKET FOR CHRONIC GVHD BY COUNTRY, 2021-2031,($MILLION)
  • TABLE 15. GLOBAL GRAFT VERSUS HOST DISEASE MARKET, BY END USE, 2021-2031,($MILLION)
  • TABLE 16. GRAFT VERSUS HOST DISEASE MARKET REVENUE, FOR HOSPITALS PHARMACIES, BY REGION , 2021-2031,($MILLION)
  • TABLE 17. GRAFT VERSUS HOST DISEASE MARKET FOR HOSPITALS PHARMACIES BY COUNTRY, 2021-2031,($MILLION)
  • TABLE 18. GRAFT VERSUS HOST DISEASE MARKET REVENUE, FOR RETAIL PHARMACIES, BY REGION , 2021-2031,($MILLION)
  • TABLE 19. GRAFT VERSUS HOST DISEASE MARKET FOR RETAIL PHARMACIES BY COUNTRY, 2021-2031,($MILLION)
  • TABLE 20. GRAFT VERSUS HOST DISEASE MARKET REVENUE, FOR ONLINE PHARMACIES, BY REGION , 2021-2031,($MILLION)
  • TABLE 21. GRAFT VERSUS HOST DISEASE MARKET FOR ONLINE PHARMACIES BY COUNTRY, 2021-2031,($MILLION)
  • TABLE 22. GRAFT VERSUS HOST DISEASE MARKET, BY REGION, 2021-2031,($MILLION)
  • TABLE 23. NORTH AMERICA GRAFT VERSUS HOST DISEASE MARKET, BY PRODUCT TYPE, 2021-2031,($MILLION)
  • TABLE 24. NORTH AMERICA GRAFT VERSUS HOST DISEASE MARKET, BY TREATMENT TYPE, 2021-2031,($MILLION)
  • TABLE 25. NORTH AMERICA GRAFT VERSUS HOST DISEASE MARKET, BY END USE, 2021-2031,($MILLION)
  • TABLE 26. NORTH AMERICA GRAFT VERSUS HOST DISEASE MARKET, BY COUNTRY, 2021-2031,($MILLION)
  • TABLE 27. U.S. GRAFT VERSUS HOST DISEASE MARKET, BY PRODUCT TYPE, 2021-2031,($MILLION)
  • TABLE 28. U.S. GRAFT VERSUS HOST DISEASE MARKET, BY TREATMENT TYPE, 2021-2031,($MILLION)
  • TABLE 29. U.S. GRAFT VERSUS HOST DISEASE MARKET, BY END USE, 2021-2031,($MILLION)
  • TABLE 30. CANADA GRAFT VERSUS HOST DISEASE MARKET, BY PRODUCT TYPE, 2021-2031,($MILLION)
  • TABLE 31. CANADA GRAFT VERSUS HOST DISEASE MARKET, BY TREATMENT TYPE, 2021-2031,($MILLION)
  • TABLE 32. CANADA GRAFT VERSUS HOST DISEASE MARKET, BY END USE, 2021-2031,($MILLION)
  • TABLE 33. MEXICO GRAFT VERSUS HOST DISEASE MARKET, BY PRODUCT TYPE, 2021-2031,($MILLION)
  • TABLE 34. MEXICO GRAFT VERSUS HOST DISEASE MARKET, BY TREATMENT TYPE, 2021-2031,($MILLION)
  • TABLE 35. MEXICO GRAFT VERSUS HOST DISEASE MARKET, BY END USE, 2021-2031,($MILLION)
  • TABLE 36. EUROPE GRAFT VERSUS HOST DISEASE MARKET, BY PRODUCT TYPE, 2021-2031,($MILLION)
  • TABLE 37. EUROPE GRAFT VERSUS HOST DISEASE MARKET, BY TREATMENT TYPE, 2021-2031,($MILLION)
  • TABLE 38. EUROPE GRAFT VERSUS HOST DISEASE MARKET, BY END USE, 2021-2031,($MILLION)
  • TABLE 39. EUROPE GRAFT VERSUS HOST DISEASE MARKET, BY COUNTRY, 2021-2031,($MILLION)
  • TABLE 40. GERMANY GRAFT VERSUS HOST DISEASE MARKET, BY PRODUCT TYPE, 2021-2031,($MILLION)
  • TABLE 41. GERMANY GRAFT VERSUS HOST DISEASE MARKET, BY TREATMENT TYPE, 2021-2031,($MILLION)
  • TABLE 42. GERMANY GRAFT VERSUS HOST DISEASE MARKET, BY END USE, 2021-2031,($MILLION)
  • TABLE 43. FRANCE GRAFT VERSUS HOST DISEASE MARKET, BY PRODUCT TYPE, 2021-2031,($MILLION)
  • TABLE 44. FRANCE GRAFT VERSUS HOST DISEASE MARKET, BY TREATMENT TYPE, 2021-2031,($MILLION)
  • TABLE 45. FRANCE GRAFT VERSUS HOST DISEASE MARKET, BY END USE, 2021-2031,($MILLION)
  • TABLE 46. UNITED KINGDOM GRAFT VERSUS HOST DISEASE MARKET, BY PRODUCT TYPE, 2021-2031,($MILLION)
  • TABLE 47. UNITED KINGDOM GRAFT VERSUS HOST DISEASE MARKET, BY TREATMENT TYPE, 2021-2031,($MILLION)
  • TABLE 48. UNITED KINGDOM GRAFT VERSUS HOST DISEASE MARKET, BY END USE, 2021-2031,($MILLION)
  • TABLE 49. ITALY GRAFT VERSUS HOST DISEASE MARKET, BY PRODUCT TYPE, 2021-2031,($MILLION)
  • TABLE 50. ITALY GRAFT VERSUS HOST DISEASE MARKET, BY TREATMENT TYPE, 2021-2031,($MILLION)
  • TABLE 51. ITALY GRAFT VERSUS HOST DISEASE MARKET, BY END USE, 2021-2031,($MILLION)
  • TABLE 52. SPAIN GRAFT VERSUS HOST DISEASE MARKET, BY PRODUCT TYPE, 2021-2031,($MILLION)
  • TABLE 53. SPAIN GRAFT VERSUS HOST DISEASE MARKET, BY TREATMENT TYPE, 2021-2031,($MILLION)
  • TABLE 54. SPAIN GRAFT VERSUS HOST DISEASE MARKET, BY END USE, 2021-2031,($MILLION)
  • TABLE 55. REST OF EUROPE GRAFT VERSUS HOST DISEASE MARKET, BY PRODUCT TYPE, 2021-2031,($MILLION)
  • TABLE 56. REST OF EUROPE GRAFT VERSUS HOST DISEASE MARKET, BY TREATMENT TYPE, 2021-2031,($MILLION)
  • TABLE 57. REST OF EUROPE GRAFT VERSUS HOST DISEASE MARKET, BY END USE, 2021-2031,($MILLION)
  • TABLE 58. ASIA-PACIFIC GRAFT VERSUS HOST DISEASE MARKET, BY PRODUCT TYPE, 2021-2031,($MILLION)
  • TABLE 59. ASIA-PACIFIC GRAFT VERSUS HOST DISEASE MARKET, BY TREATMENT TYPE, 2021-2031,($MILLION)
  • TABLE 60. ASIA-PACIFIC GRAFT VERSUS HOST DISEASE MARKET, BY END USE, 2021-2031,($MILLION)
  • TABLE 61. ASIA-PACIFIC GRAFT VERSUS HOST DISEASE MARKET, BY COUNTRY, 2021-2031,($MILLION)
  • TABLE 62. JAPAN GRAFT VERSUS HOST DISEASE MARKET, BY PRODUCT TYPE, 2021-2031,($MILLION)
  • TABLE 63. JAPAN GRAFT VERSUS HOST DISEASE MARKET, BY TREATMENT TYPE, 2021-2031,($MILLION)
  • TABLE 64. JAPAN GRAFT VERSUS HOST DISEASE MARKET, BY END USE, 2021-2031,($MILLION)
  • TABLE 65. CHINA GRAFT VERSUS HOST DISEASE MARKET, BY PRODUCT TYPE, 2021-2031,($MILLION)
  • TABLE 66. CHINA GRAFT VERSUS HOST DISEASE MARKET, BY TREATMENT TYPE, 2021-2031,($MILLION)
  • TABLE 67. CHINA GRAFT VERSUS HOST DISEASE MARKET, BY END USE, 2021-2031,($MILLION)
  • TABLE 68. AUSTRALIA GRAFT VERSUS HOST DISEASE MARKET, BY PRODUCT TYPE, 2021-2031,($MILLION)
  • TABLE 69. AUSTRALIA GRAFT VERSUS HOST DISEASE MARKET, BY TREATMENT TYPE, 2021-2031,($MILLION)
  • TABLE 70. AUSTRALIA GRAFT VERSUS HOST DISEASE MARKET, BY END USE, 2021-2031,($MILLION)
  • TABLE 71. INDIA GRAFT VERSUS HOST DISEASE MARKET, BY PRODUCT TYPE, 2021-2031,($MILLION)
  • TABLE 72. INDIA GRAFT VERSUS HOST DISEASE MARKET, BY TREATMENT TYPE, 2021-2031,($MILLION)
  • TABLE 73. INDIA GRAFT VERSUS HOST DISEASE MARKET, BY END USE, 2021-2031,($MILLION)
  • TABLE 74. SOUTH KOREA GRAFT VERSUS HOST DISEASE MARKET, BY PRODUCT TYPE, 2021-2031,($MILLION)
  • TABLE 75. SOUTH KOREA GRAFT VERSUS HOST DISEASE MARKET, BY TREATMENT TYPE, 2021-2031,($MILLION)
  • TABLE 76. SOUTH KOREA GRAFT VERSUS HOST DISEASE MARKET, BY END USE, 2021-2031,($MILLION)
  • TABLE 77. REST OF ASIA-PACIFIC GRAFT VERSUS HOST DISEASE MARKET, BY PRODUCT TYPE, 2021-2031,($MILLION)
  • TABLE 78. REST OF ASIA-PACIFIC GRAFT VERSUS HOST DISEASE MARKET, BY TREATMENT TYPE, 2021-2031,($MILLION)
  • TABLE 79. REST OF ASIA-PACIFIC GRAFT VERSUS HOST DISEASE MARKET, BY END USE, 2021-2031,($MILLION)
  • TABLE 80. LAMEA GRAFT VERSUS HOST DISEASE MARKET, BY PRODUCT TYPE, 2021-2031,($MILLION)
  • TABLE 81. LAMEA GRAFT VERSUS HOST DISEASE MARKET, BY TREATMENT TYPE, 2021-2031,($MILLION)
  • TABLE 82. LAMEA GRAFT VERSUS HOST DISEASE MARKET, BY END USE, 2021-2031,($MILLION)
  • TABLE 83. LAMEA GRAFT VERSUS HOST DISEASE MARKET, BY COUNTRY, 2021-2031,($MILLION)
  • TABLE 84. BRAZIL GRAFT VERSUS HOST DISEASE MARKET, BY PRODUCT TYPE, 2021-2031,($MILLION)
  • TABLE 85. BRAZIL GRAFT VERSUS HOST DISEASE MARKET, BY TREATMENT TYPE, 2021-2031,($MILLION)
  • TABLE 86. BRAZIL GRAFT VERSUS HOST DISEASE MARKET, BY END USE, 2021-2031,($MILLION)
  • TABLE 87. TURKEY GRAFT VERSUS HOST DISEASE MARKET, BY PRODUCT TYPE, 2021-2031,($MILLION)
  • TABLE 88. TURKEY GRAFT VERSUS HOST DISEASE MARKET, BY TREATMENT TYPE, 2021-2031,($MILLION)
  • TABLE 89. TURKEY GRAFT VERSUS HOST DISEASE MARKET, BY END USE, 2021-2031,($MILLION)
  • TABLE 90. SOUTH AFRICA GRAFT VERSUS HOST DISEASE MARKET, BY PRODUCT TYPE, 2021-2031,($MILLION)
  • TABLE 91. SOUTH AFRICA GRAFT VERSUS HOST DISEASE MARKET, BY TREATMENT TYPE, 2021-2031,($MILLION)
  • TABLE 92. SOUTH AFRICA GRAFT VERSUS HOST DISEASE MARKET, BY END USE, 2021-2031,($MILLION)
  • TABLE 93. REST OF LAMEA GRAFT VERSUS HOST DISEASE MARKET, BY PRODUCT TYPE, 2021-2031,($MILLION)
  • TABLE 94. REST OF LAMEA GRAFT VERSUS HOST DISEASE MARKET, BY TREATMENT TYPE, 2021-2031,($MILLION)
  • TABLE 95. REST OF LAMEA GRAFT VERSUS HOST DISEASE MARKET, BY END USE, 2021-2031,($MILLION)
  • TABLE 96.SANOFI: COMPANY SNAPSHOT
  • TABLE 97.SANOFI: OPERATING SEGMENTS
  • TABLE 98.SANOFI: PRODUCT PORTFOLIO
  • TABLE 99.SANOFI: NET SALES,
  • TABLE 100.SANOFI: KEY STRATERGIES
  • TABLE 101.NOVARTIS AG: COMPANY SNAPSHOT
  • TABLE 102.NOVARTIS AG: OPERATING SEGMENTS
  • TABLE 103.NOVARTIS AG: PRODUCT PORTFOLIO
  • TABLE 104.NOVARTIS AG: NET SALES,
  • TABLE 105.NOVARTIS AG: KEY STRATERGIES
  • TABLE 106.MERCK & CO.: COMPANY SNAPSHOT
  • TABLE 107.MERCK & CO.: OPERATING SEGMENTS
  • TABLE 108.MERCK & CO.: PRODUCT PORTFOLIO
  • TABLE 109.MERCK & CO.: NET SALES,
  • TABLE 110.MERCK & CO.: KEY STRATERGIES
  • TABLE 111.ABBVIE INC: COMPANY SNAPSHOT
  • TABLE 112.ABBVIE INC: OPERATING SEGMENTS
  • TABLE 113.ABBVIE INC: PRODUCT PORTFOLIO
  • TABLE 114.ABBVIE INC: NET SALES,
  • TABLE 115.ABBVIE INC: KEY STRATERGIES
  • TABLE 116.PFIZER INC.: COMPANY SNAPSHOT
  • TABLE 117.PFIZER INC.: OPERATING SEGMENTS
  • TABLE 118.PFIZER INC.: PRODUCT PORTFOLIO
  • TABLE 119.PFIZER INC.: NET SALES,
  • TABLE 120.PFIZER INC.: KEY STRATERGIES
  • TABLE 121.ACCORD HEALTHCARE LIMITED: COMPANY SNAPSHOT
  • TABLE 122.ACCORD HEALTHCARE LIMITED: OPERATING SEGMENTS
  • TABLE 123.ACCORD HEALTHCARE LIMITED: PRODUCT PORTFOLIO
  • TABLE 124.ACCORD HEALTHCARE LIMITED: NET SALES,
  • TABLE 125.ACCORD HEALTHCARE LIMITED: KEY STRATERGIES
  • TABLE 126.BRISTOL MYER SQUIBB: COMPANY SNAPSHOT
  • TABLE 127.BRISTOL MYER SQUIBB: OPERATING SEGMENTS
  • TABLE 128.BRISTOL MYER SQUIBB: PRODUCT PORTFOLIO
  • TABLE 129.BRISTOL MYER SQUIBB: NET SALES,
  • TABLE 130.BRISTOL MYER SQUIBB: KEY STRATERGIES
  • TABLE 131.ASAHI KASEI CORPORATION: COMPANY SNAPSHOT
  • TABLE 132.ASAHI KASEI CORPORATION: OPERATING SEGMENTS
  • TABLE 133.ASAHI KASEI CORPORATION: PRODUCT PORTFOLIO
  • TABLE 134.ASAHI KASEI CORPORATION: NET SALES,
  • TABLE 135.ASAHI KASEI CORPORATION: KEY STRATERGIES
  • TABLE 136.GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
  • TABLE 137.GLAXOSMITHKLINE PLC: OPERATING SEGMENTS
  • TABLE 138.GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
  • TABLE 139.GLAXOSMITHKLINE PLC: NET SALES,
  • TABLE 140.GLAXOSMITHKLINE PLC: KEY STRATERGIES
  • TABLE 141.INCYTE CORPORATION: COMPANY SNAPSHOT
  • TABLE 142.INCYTE CORPORATION: OPERATING SEGMENTS
  • TABLE 143.INCYTE CORPORATION: PRODUCT PORTFOLIO
  • TABLE 144.INCYTE CORPORATION: NET SALES,
  • TABLE 145.INCYTE CORPORATION: KEY STRATERGIES

LIST OF FIGURES

  • FIGURE 1.GRAFT VERSUS HOST DISEASE MARKET SEGMENTATION
  • FIGURE 2.GRAFT VERSUS HOST DISEASE MARKET,2021-2031
  • FIGURE 3.GRAFT VERSUS HOST DISEASE MARKET,2021-2031
  • FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
  • FIGURE 5.PORTER FIVE-1
  • FIGURE 6.PORTER FIVE-2
  • FIGURE 7.PORTER FIVE-3
  • FIGURE 8.PORTER FIVE-4
  • FIGURE 9.PORTER FIVE-5
  • FIGURE 10.TOP PLAYER POSITIONING
  • FIGURE 11.GRAFT VERSUS HOST DISEASE MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 12.GRAFT VERSUS HOST DISEASE MARKET,BY PRODUCT TYPE,2021(%)
  • FIGURE 13.COMPARATIVE SHARE ANALYSIS OF CORTICOSTEROIDS GRAFT VERSUS HOST DISEASE MARKET,2021-2031(%)
  • FIGURE 14.COMPARATIVE SHARE ANALYSIS OF MONOCLONAL ANTIBODIES GRAFT VERSUS HOST DISEASE MARKET,2021-2031(%)
  • FIGURE 15.COMPARATIVE SHARE ANALYSIS OF IMMUNOSUPPRESSANTS GRAFT VERSUS HOST DISEASE MARKET,2021-2031(%)
  • FIGURE 16.COMPARATIVE SHARE ANALYSIS OF OTHERS GRAFT VERSUS HOST DISEASE MARKET,2021-2031(%)
  • FIGURE 17.GRAFT VERSUS HOST DISEASE MARKET,BY TREATMENT TYPE,2021(%)
  • FIGURE 18.COMPARATIVE SHARE ANALYSIS OF ACUTE GVHD GRAFT VERSUS HOST DISEASE MARKET,2021-2031(%)
  • FIGURE 19.COMPARATIVE SHARE ANALYSIS OF CHRONIC GVHD GRAFT VERSUS HOST DISEASE MARKET,2021-2031(%)
  • FIGURE 20.GRAFT VERSUS HOST DISEASE MARKET,BY END USE,2021(%)
  • FIGURE 21.COMPARATIVE SHARE ANALYSIS OF HOSPITALS PHARMACIES GRAFT VERSUS HOST DISEASE MARKET,2021-2031(%)
  • FIGURE 22.COMPARATIVE SHARE ANALYSIS OF RETAIL PHARMACIES GRAFT VERSUS HOST DISEASE MARKET,2021-2031(%)
  • FIGURE 23.COMPARATIVE SHARE ANALYSIS OF ONLINE PHARMACIES GRAFT VERSUS HOST DISEASE MARKET,2021-2031(%)
  • FIGURE 24.GRAFT VERSUS HOST DISEASE MARKET BY REGION,2021
  • FIGURE 25.U.S. GRAFT VERSUS HOST DISEASE MARKET,2021-2031($MILLION)
  • FIGURE 26.CANADA GRAFT VERSUS HOST DISEASE MARKET,2021-2031($MILLION)
  • FIGURE 27.MEXICO GRAFT VERSUS HOST DISEASE MARKET,2021-2031($MILLION)
  • FIGURE 28.GERMANY GRAFT VERSUS HOST DISEASE MARKET,2021-2031($MILLION)
  • FIGURE 29.FRANCE GRAFT VERSUS HOST DISEASE MARKET,2021-2031($MILLION)
  • FIGURE 30.UNITED KINGDOM GRAFT VERSUS HOST DISEASE MARKET,2021-2031($MILLION)
  • FIGURE 31.ITALY GRAFT VERSUS HOST DISEASE MARKET,2021-2031($MILLION)
  • FIGURE 32.SPAIN GRAFT VERSUS HOST DISEASE MARKET,2021-2031($MILLION)
  • FIGURE 33.REST OF EUROPE GRAFT VERSUS HOST DISEASE MARKET,2021-2031($MILLION)
  • FIGURE 34.JAPAN GRAFT VERSUS HOST DISEASE MARKET,2021-2031($MILLION)
  • FIGURE 35.CHINA GRAFT VERSUS HOST DISEASE MARKET,2021-2031($MILLION)
  • FIGURE 36.AUSTRALIA GRAFT VERSUS HOST DISEASE MARKET,2021-2031($MILLION)
  • FIGURE 37.INDIA GRAFT VERSUS HOST DISEASE MARKET,2021-2031($MILLION)
  • FIGURE 38.SOUTH KOREA GRAFT VERSUS HOST DISEASE MARKET,2021-2031($MILLION)
  • FIGURE 39.REST OF ASIA-PACIFIC GRAFT VERSUS HOST DISEASE MARKET,2021-2031($MILLION)
  • FIGURE 40.BRAZIL GRAFT VERSUS HOST DISEASE MARKET,2021-2031($MILLION)
  • FIGURE 41.TURKEY GRAFT VERSUS HOST DISEASE MARKET,2021-2031($MILLION)
  • FIGURE 42.SOUTH AFRICA GRAFT VERSUS HOST DISEASE MARKET,2021-2031($MILLION)
  • FIGURE 43.REST OF LAMEA GRAFT VERSUS HOST DISEASE MARKET,2021-2031($MILLION)
  • FIGURE 44. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 45. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 46. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 47.PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 48.COMPETITIVE DASHBOARD
  • FIGURE 49.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
  • FIGURE 50.SANOFI.: NET SALES ,($MILLION)
  • FIGURE 51.NOVARTIS AG.: NET SALES ,($MILLION)
  • FIGURE 52.MERCK & CO..: NET SALES ,($MILLION)
  • FIGURE 53.ABBVIE INC.: NET SALES ,($MILLION)
  • FIGURE 54.PFIZER INC..: NET SALES ,($MILLION)
  • FIGURE 55.ACCORD HEALTHCARE LIMITED.: NET SALES ,($MILLION)
  • FIGURE 56.BRISTOL MYER SQUIBB.: NET SALES ,($MILLION)
  • FIGURE 57.ASAHI KASEI CORPORATION.: NET SALES ,($MILLION)
  • FIGURE 58.GLAXOSMITHKLINE PLC.: NET SALES ,($MILLION)
  • FIGURE 59.INCYTE CORPORATION.: NET SALES ,($MILLION)
目次
Product Code: A11929

The global Graft Versus Host Disease Market was valued at $2,968.6 million in 2021, and is projected to reach $10,375.3 million by 2031, registering a CAGR of 13.5% from 2022 to 2031.

Graft versus host disease (GVHD) is a condition that might occur after an allogeneic transplant (bone marrow transplant). In GVHD, the donated bone marrow or peripheral blood stem cells view the recipient's body as foreign, and the donated cells/bone marrow attack the body. There are two forms of GVHD: acute graft versus host disease (aGVHD) and chronic graft versus host disease (cGVHD).

The pathophysiology of aGVHD and cGVHD remains incompletely understood. One commonly quoted model suggests three distinct stages in the development of aGVHD: a conditioning regimen, which damages host tissues, including intestinal mucosa and liver; activation of donor T cells against host antigens & subsequent clonal T-cell expansion; and release of inflammatory cytokines such as interleukin 1 (IL-1) & tumor necrosis factor (TNFα), leading to further host tissue damage. Several mechanisms have been implicated in cGVHD pathogenesis, including persistence of donor-derived alloreactive T cells, autoreactive T cells, B cells producing antibodies against the host, and mechanisms of chronic inflammation leading to end organ fibrosis.

Despite decades of research and improvements in post-transplant immunosuppressive therapies, graft-versus-host disease (GVHD) remains a significant cause of morbidity and mortality in allogenic hematopoietic stem-cell transplant (HSCT) recipients.

The COVID-19 pandemic has had an impact on a variety of businesses around the world. The Graft Versus Host Disease Market had a significant impact as well. To halt the spread of COVID-19, governments around the world implemented harsh restrictions such as border locks, lockdowns, and tight social distancing measures. These measures had a significant impact on the global economy, affecting a variety of industries. Pharmaceutical and biotech companies together with governments around the globe work to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline.

Impact of COVID-19: The COVID-19 pandemic has significantly changed the landscape of kidney transplantation in the U.S. and worldwide. In addition to adversely impacting allograft and patient survival in post kidney transplant recipients, the current pandemic has affected all aspects of transplant care, including transplant referrals and listing, organ donation rates, organ procurement and shipping, and waitlist mortality.

As kidney transplantation rates declined, so did organ procurement rates. The UK reported a 39% decrease in referrals of organs to OPOs. France reported a 16% decrease in all deceased organ procurement rates as compared to previous years. Part of these declines were due to procurement challenges faced by transplant programs and organizations, such as insufficient testing capabilities and delayed COVID-19 test results, limited operating room availabilities, and mandates for the avoidance of nonessential clinical activities to preserve personnel and protective equipment.

Therefore, the overall impact of COVID-19 remains negative on graft versus host disease market due to decline in number of transplantation procedure. The transplant procedure requires the routine use of reusable equipment with close contact with patients. This increases the risk of disease transmission.

Increase in number of grafts versus host disease, which arises predominantly due to rise in number of allogenic transplantations. Also, increase in disease diagnosis rate and increase in number of products available for the treatment of graft versus host disease are the factors fueling the growth of the market.

According to preliminary data from the Organ Procurement and Transplantation Network, in 2020 organ donation from deceased donors in the U.S. set an all-time record. A total of 12,587 people provided one or more organs to save and enhance the lives of others, representing an increase of six percent over 2019.

Moreover, much of the increase in deceased donation was made possible by donors representing less traditional medical criteria. The most common age range of deceased donors was 50 to 64. The 3,726 donors in this category increased by 7.9 percent over 2019. Donation increased significantly among individuals who died of cardiorespiratory failure as opposed to brain death; the 3,223 donors after cardiorespiratory death (DCD donors) increased by 18.6 percent over the total in 2019.

According to Organ Donation Statistics, 105,988 number of men, women, and children are on the national transplant waiting list, whereas 17 people die each day waiting for the organ transplant and an estimated 40,000 transplants were performed in 2021.

Complications such as allergic reactions, which cannot be detected by computational biology and other post-surgery complications, unfavorable government scenario, the high initial cost and maintenance costs of the instruments, lack of standardization, and shortage of skilled workforce are expected to be the significant restraints to market growth during the forecast period.

The graft versus host disease market is segmented on the basis of product, diagnosis, types, end use, and region. By product the market is segmented into corticosteroids, monoclonal antibodies, immunosuppressants and others. On the basis of type the segment is divided into acute and chronic. On the basis of end use the segment is divided into hospital pharmacies, retail pharmacies and online pharmacies.

Region-wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Some of the major companies that operate in the graft versus host disease market are AbbVie, Asahi Kasei, Bristol Myer Squibb, GlaxoSmithKline, Incyte Corporation, Medac GmbH, Merck & co., Novartis, Pfizer and Sanofi.

Key Benefits For Stakeholders

The study provides an in-depth analysis of the graft versus host disease market, and the current graft versus host disease market trends and future estimations to elucidate imminent investment pockets.

It presents a quantitative analysis of the market from 2022 to 2031 to enable stakeholders to capitalize on the prevailing market graft versus host disease market opportunity.

Extensive analysis of the market based on procedures and services assists to understand the trends in the graft versus host disease industry.

Key players and their strategies are thoroughly analyzed to understand the competitive outlook of the market.

Key Market Segments

By Product Type

  • Corticosteroids
  • Monoclonal antibodies
  • Immunosuppressants
  • Others

By Treatment Type

  • Acute GVHD
  • Chronic GVHD

By End Use

  • Hospitals Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Turkey
    • South Africa
    • Rest of LAMEA
  • Key Market Players
    • Sanofi
    • Novartis AG
    • Merck & Co.
    • Abbvie Inc
    • Pfizer Inc.
    • Accord Healthcare Limited
    • Bristol Myer Squibb
    • Asahi Kasei Corporation
    • Glaxosmithkline plc
    • Incyte Corporation

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key market segments
  • 1.3.Key benefits to the stakeholders
  • 1.4.Research Methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
  • 3.3.Porter's five forces analysis
  • 3.4.Top player positioning
  • 3.5.Market dynamics
    • 3.5.1.Drivers
    • 3.5.2.Restraints
    • 3.5.3.Opportunities
  • 3.6.COVID-19 Impact Analysis on the market

CHAPTER 4: GRAFT VERSUS HOST DISEASE MARKET, BY PRODUCT TYPE

  • 4.1 Overview
    • 4.1.1 Market size and forecast
  • 4.2 Corticosteroids
    • 4.2.1 Key market trends, growth factors and opportunities
    • 4.2.2 Market size and forecast, by region
    • 4.2.3 Market analysis by country
  • 4.3 Monoclonal antibodies
    • 4.3.1 Key market trends, growth factors and opportunities
    • 4.3.2 Market size and forecast, by region
    • 4.3.3 Market analysis by country
  • 4.4 Immunosuppressants
    • 4.4.1 Key market trends, growth factors and opportunities
    • 4.4.2 Market size and forecast, by region
    • 4.4.3 Market analysis by country
  • 4.5 Others
    • 4.5.1 Key market trends, growth factors and opportunities
    • 4.5.2 Market size and forecast, by region
    • 4.5.3 Market analysis by country

CHAPTER 5: GRAFT VERSUS HOST DISEASE MARKET, BY TREATMENT TYPE

  • 5.1 Overview
    • 5.1.1 Market size and forecast
  • 5.2 Acute GVHD
    • 5.2.1 Key market trends, growth factors and opportunities
    • 5.2.2 Market size and forecast, by region
    • 5.2.3 Market analysis by country
  • 5.3 Chronic GVHD
    • 5.3.1 Key market trends, growth factors and opportunities
    • 5.3.2 Market size and forecast, by region
    • 5.3.3 Market analysis by country

CHAPTER 6: GRAFT VERSUS HOST DISEASE MARKET, BY END USE

  • 6.1 Overview
    • 6.1.1 Market size and forecast
  • 6.2 Hospitals Pharmacies
    • 6.2.1 Key market trends, growth factors and opportunities
    • 6.2.2 Market size and forecast, by region
    • 6.2.3 Market analysis by country
  • 6.3 Retail Pharmacies
    • 6.3.1 Key market trends, growth factors and opportunities
    • 6.3.2 Market size and forecast, by region
    • 6.3.3 Market analysis by country
  • 6.4 Online Pharmacies
    • 6.4.1 Key market trends, growth factors and opportunities
    • 6.4.2 Market size and forecast, by region
    • 6.4.3 Market analysis by country

CHAPTER 7: GRAFT VERSUS HOST DISEASE MARKET, BY REGION

  • 7.1 Overview
    • 7.1.1 Market size and forecast
  • 7.2 North America
    • 7.2.1 Key trends and opportunities
    • 7.2.2 North America Market size and forecast, by Product Type
    • 7.2.3 North America Market size and forecast, by Treatment Type
    • 7.2.4 North America Market size and forecast, by End Use
    • 7.2.5 North America Market size and forecast, by country
      • 7.2.5.1 U.S.
      • 7.2.5.1.1 Market size and forecast, by Product Type
      • 7.2.5.1.2 Market size and forecast, by Treatment Type
      • 7.2.5.1.3 Market size and forecast, by End Use
      • 7.2.5.2 Canada
      • 7.2.5.2.1 Market size and forecast, by Product Type
      • 7.2.5.2.2 Market size and forecast, by Treatment Type
      • 7.2.5.2.3 Market size and forecast, by End Use
      • 7.2.5.3 Mexico
      • 7.2.5.3.1 Market size and forecast, by Product Type
      • 7.2.5.3.2 Market size and forecast, by Treatment Type
      • 7.2.5.3.3 Market size and forecast, by End Use
  • 7.3 Europe
    • 7.3.1 Key trends and opportunities
    • 7.3.2 Europe Market size and forecast, by Product Type
    • 7.3.3 Europe Market size and forecast, by Treatment Type
    • 7.3.4 Europe Market size and forecast, by End Use
    • 7.3.5 Europe Market size and forecast, by country
      • 7.3.5.1 Germany
      • 7.3.5.1.1 Market size and forecast, by Product Type
      • 7.3.5.1.2 Market size and forecast, by Treatment Type
      • 7.3.5.1.3 Market size and forecast, by End Use
      • 7.3.5.2 France
      • 7.3.5.2.1 Market size and forecast, by Product Type
      • 7.3.5.2.2 Market size and forecast, by Treatment Type
      • 7.3.5.2.3 Market size and forecast, by End Use
      • 7.3.5.3 United Kingdom
      • 7.3.5.3.1 Market size and forecast, by Product Type
      • 7.3.5.3.2 Market size and forecast, by Treatment Type
      • 7.3.5.3.3 Market size and forecast, by End Use
      • 7.3.5.4 Italy
      • 7.3.5.4.1 Market size and forecast, by Product Type
      • 7.3.5.4.2 Market size and forecast, by Treatment Type
      • 7.3.5.4.3 Market size and forecast, by End Use
      • 7.3.5.5 Spain
      • 7.3.5.5.1 Market size and forecast, by Product Type
      • 7.3.5.5.2 Market size and forecast, by Treatment Type
      • 7.3.5.5.3 Market size and forecast, by End Use
      • 7.3.5.6 Rest of Europe
      • 7.3.5.6.1 Market size and forecast, by Product Type
      • 7.3.5.6.2 Market size and forecast, by Treatment Type
      • 7.3.5.6.3 Market size and forecast, by End Use
  • 7.4 Asia-Pacific
    • 7.4.1 Key trends and opportunities
    • 7.4.2 Asia-Pacific Market size and forecast, by Product Type
    • 7.4.3 Asia-Pacific Market size and forecast, by Treatment Type
    • 7.4.4 Asia-Pacific Market size and forecast, by End Use
    • 7.4.5 Asia-Pacific Market size and forecast, by country
      • 7.4.5.1 Japan
      • 7.4.5.1.1 Market size and forecast, by Product Type
      • 7.4.5.1.2 Market size and forecast, by Treatment Type
      • 7.4.5.1.3 Market size and forecast, by End Use
      • 7.4.5.2 China
      • 7.4.5.2.1 Market size and forecast, by Product Type
      • 7.4.5.2.2 Market size and forecast, by Treatment Type
      • 7.4.5.2.3 Market size and forecast, by End Use
      • 7.4.5.3 Australia
      • 7.4.5.3.1 Market size and forecast, by Product Type
      • 7.4.5.3.2 Market size and forecast, by Treatment Type
      • 7.4.5.3.3 Market size and forecast, by End Use
      • 7.4.5.4 India
      • 7.4.5.4.1 Market size and forecast, by Product Type
      • 7.4.5.4.2 Market size and forecast, by Treatment Type
      • 7.4.5.4.3 Market size and forecast, by End Use
      • 7.4.5.5 South Korea
      • 7.4.5.5.1 Market size and forecast, by Product Type
      • 7.4.5.5.2 Market size and forecast, by Treatment Type
      • 7.4.5.5.3 Market size and forecast, by End Use
      • 7.4.5.6 Rest of Asia-Pacific
      • 7.4.5.6.1 Market size and forecast, by Product Type
      • 7.4.5.6.2 Market size and forecast, by Treatment Type
      • 7.4.5.6.3 Market size and forecast, by End Use
  • 7.5 LAMEA
    • 7.5.1 Key trends and opportunities
    • 7.5.2 LAMEA Market size and forecast, by Product Type
    • 7.5.3 LAMEA Market size and forecast, by Treatment Type
    • 7.5.4 LAMEA Market size and forecast, by End Use
    • 7.5.5 LAMEA Market size and forecast, by country
      • 7.5.5.1 Brazil
      • 7.5.5.1.1 Market size and forecast, by Product Type
      • 7.5.5.1.2 Market size and forecast, by Treatment Type
      • 7.5.5.1.3 Market size and forecast, by End Use
      • 7.5.5.2 Turkey
      • 7.5.5.2.1 Market size and forecast, by Product Type
      • 7.5.5.2.2 Market size and forecast, by Treatment Type
      • 7.5.5.2.3 Market size and forecast, by End Use
      • 7.5.5.3 South Africa
      • 7.5.5.3.1 Market size and forecast, by Product Type
      • 7.5.5.3.2 Market size and forecast, by Treatment Type
      • 7.5.5.3.3 Market size and forecast, by End Use
      • 7.5.5.4 Rest of LAMEA
      • 7.5.5.4.1 Market size and forecast, by Product Type
      • 7.5.5.4.2 Market size and forecast, by Treatment Type
      • 7.5.5.4.3 Market size and forecast, by End Use

CHAPTER 8: COMPANY LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Key developments

CHAPTER 9: COMPANY PROFILES

  • 9.1 Sanofi
    • 9.1.1 Company overview
    • 9.1.2 Company snapshot
    • 9.1.3 Operating business segments
    • 9.1.4 Product portfolio
    • 9.1.5 Business performance
    • 9.1.6 Key strategic moves and developments
  • 9.2 Novartis AG
    • 9.2.1 Company overview
    • 9.2.2 Company snapshot
    • 9.2.3 Operating business segments
    • 9.2.4 Product portfolio
    • 9.2.5 Business performance
    • 9.2.6 Key strategic moves and developments
  • 9.3 Merck & Co.
    • 9.3.1 Company overview
    • 9.3.2 Company snapshot
    • 9.3.3 Operating business segments
    • 9.3.4 Product portfolio
    • 9.3.5 Business performance
    • 9.3.6 Key strategic moves and developments
  • 9.4 Abbvie Inc
    • 9.4.1 Company overview
    • 9.4.2 Company snapshot
    • 9.4.3 Operating business segments
    • 9.4.4 Product portfolio
    • 9.4.5 Business performance
    • 9.4.6 Key strategic moves and developments
  • 9.5 Pfizer Inc.
    • 9.5.1 Company overview
    • 9.5.2 Company snapshot
    • 9.5.3 Operating business segments
    • 9.5.4 Product portfolio
    • 9.5.5 Business performance
    • 9.5.6 Key strategic moves and developments
  • 9.6 Accord Healthcare Limited
    • 9.6.1 Company overview
    • 9.6.2 Company snapshot
    • 9.6.3 Operating business segments
    • 9.6.4 Product portfolio
    • 9.6.5 Business performance
    • 9.6.6 Key strategic moves and developments
  • 9.7 Bristol Myer Squibb
    • 9.7.1 Company overview
    • 9.7.2 Company snapshot
    • 9.7.3 Operating business segments
    • 9.7.4 Product portfolio
    • 9.7.5 Business performance
    • 9.7.6 Key strategic moves and developments
  • 9.8 Asahi Kasei Corporation
    • 9.8.1 Company overview
    • 9.8.2 Company snapshot
    • 9.8.3 Operating business segments
    • 9.8.4 Product portfolio
    • 9.8.5 Business performance
    • 9.8.6 Key strategic moves and developments
  • 9.9 Glaxosmithkline plc
    • 9.9.1 Company overview
    • 9.9.2 Company snapshot
    • 9.9.3 Operating business segments
    • 9.9.4 Product portfolio
    • 9.9.5 Business performance
    • 9.9.6 Key strategic moves and developments
  • 9.10 Incyte Corporation
    • 9.10.1 Company overview
    • 9.10.2 Company snapshot
    • 9.10.3 Operating business segments
    • 9.10.4 Product portfolio
    • 9.10.5 Business performance
    • 9.10.6 Key strategic moves and developments